Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$6.13
$9.17
$6.06
▼
$20.56
$114.45M2.631.38 million shs834,833 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
0.00%-14.15%-44.68%-31.89%-58.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$6.13
$9.17
$6.06
▼
$20.56
$114.45M2.631.38 million shs834,833 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
0.00%-14.15%-44.68%-31.89%-58.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
2.60
Moderate Buy$41.00568.84% Upside

Current Analyst Ratings Breakdown

Latest CRBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
8/26/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
8/13/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$33.00
8/7/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$52.00 ➝ $48.00
8/7/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $35.00
7/17/2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$8.40 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$78.54M-$6.19N/AN/AN/AN/A-87.05%-74.22%11/11/2026 (Estimated)

Latest CRBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.26-$1.81-$0.55-$1.81N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
5.71
5.71

Institutional Ownership

CompanyInstitutional Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%

Insider Ownership

CompanyInsider Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3618.67 million18.02 millionOptionable

Recent News About These Companies

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068135
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Brokerages
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-corbus-pharmaceuticals-holdings-inc-nasdaq-crbp-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-09-30/
Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed in Tempo-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
September 29, 2026  |  marketscreener.comM
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370767/0/en/corbus-pharmaceuticals-announces-first-patient-dosed-in-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer.html
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)?
September 26, 2026  |  kalkinemedia.comK
Corbus Pharmaceuticals stock holds at USD 1.56
September 22, 2026  |  ad-hoc-news.deA
Corbus Pharmaceuticals Insider Ben Yong Offloads 2,000 Shares at $7.84 Each (NASDAQ: CRBP)
September 18, 2026  |  kalkinemedia.comK
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
September 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2991357/is-crbp-a-good-cannabis-investment-after-positive-obesity-study-data?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2991357
Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
September 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRBP/pressreleases/4632551/wedbush-keeps-their-buy-rating-on-corbus-pharmaceuticals-crbp/
Corbus Pharmaceuticals (NASDAQ:CRBP) Director Yong Ben Sells 2,000 Shares
September 16, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-crbp-insider-buying-and-selling-2026-09-16/
Insider Selling: Corbus Pharmaceuticals (NASDAQ:CRBP) Director Sells $15,680.00 in Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-corbus-pharmaceuticals-nasdaq-crbp-director-sells-1568000-in-stock-2026-09-15/
Corbus Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CRBP)
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-corbus-pharmaceuticals-target-of-unusually-large-options-trading-nasdaq-crbp-2026-09-15/
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-corbus-crb-913-delivers-5-weight-loss-in-phase-1b-obesity-study-2026-09-15/
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946134-corbus-pharmaceuticals-holdings-inc-crbp-phase-1b-topline-results-for-crbminus-913-in-obesity
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/corbus-pharmaceuticals-shares-rise-12-132826287.html
Corbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at HC Wainwright
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-corbus-pharmaceuticals-crbp-buy-rating-reiterated-at-hc-wainwright-2026-09-14/
Investors Purchase High Volume of Corbus Pharmaceuticals Call Options (NASDAQ:CRBP)
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-investors-purchase-high-volume-of-corbus-pharmaceuticals-call-options-nasdaq-crbp-2026-09-14/
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
September 14, 2026  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/09/61767721/corbus-pharmaceuticals-obesity-drug-avoids-depressive-effects?utm_source=snapi
Corbus obesity drug hits 5% weight loss mark in phase 1b trial
September 14, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Corbus+obesity+drug+hits+5%25+weight+loss+mark+in+phase+1b+trial/27055273.html
Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up
September 14, 2026  |  rttnews.comhttps://www.rttnews.com/3690692/corbus-announces-positive-phase-1b-weight-loss-data-showing-for-oral-candidate-crb-913-stock-up.aspx
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3360951/0/en/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-crb-913-for-the-treatment-of-obesity.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$6.13 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$6.23 +0.10 (+1.66%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas